Irinotecan
About
Therapy type: Chemotherapy
Therapy strategy: Topoisomerase I inhibition
Mappings
NCI Thesaurus: Irinotecan (ncit:C62040)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Irinotecan | |
| Sensitivity (+) | EGFR positive, Wild type KRAS | Colorectal Adenocarcinoma | Cetuximab, Irinotecan | |
| Sensitivity (+) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Irinotecan | |
| Sensitivity (+) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Irinotecan, Panitumumab | |
| Sensitivity (+) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Irinotecan, Panitumumab |